Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DermaWound Venous Stasis Formula is a topical over-the-counter (OTC) wound care ointment developed by DermaWound Products. The formulation contains 1.27% benzocaine hydrochloride as its active pharmaceutical ingredient, which functions as a local anesthetic to provide relief from the burning pain associated with chronic ulcers. In addition to benzocaine, the product incorporates a proprietary blend of sucrose (polysaccharides), calcium carbonate (minerals), and PVP-Iodine. This combination is designed to facilitate natural auto-debridement of the wound bed and promote healing in various conditions, including venous stasis ulcers, ankle ulcers, sickle cell ulcers, and burn ulcers. The product is FDA-registered and has been commercially available for nearly three decades.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DermaWound Venous Stasis Formula.